Drug-induced QTc-interval prolongation in the intensive care unit: Incidence and predictors

Journal of Pharmacy Practice

Volumn 23, Issue 1, 2010, Pages 19-24

  Ng, Tien M H ^a,b   Olsen, Keith M ^b   McCartan, Megan A ^b   Puumala, Susan E ^b   Speidel, Katie M ^b   Miller, Melissa A ^b   Sears, Tom D ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Arrhythmia; Critical care; Drug therapy; Drug toxicity; Intensive care; Torsade de pointes

Indexed keywords

AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CIPROFLOXACIN; DISOPYRAMIDE; DIURETIC AGENT; DOFETILIDE; GATIFLOXACIN; HALOPERIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERTENSIVE AGENT; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PROCAINAMIDE; QUINIDINE; SOTALOL;

ADULT; APACHE; ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEART ELECTROPHYSIOLOGY; HEART REPOLARIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PROGNOSIS; QT PROLONGATION;

EID: 77949352952     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190009356549     Document Type: Article

References (29)

1. Al-Khatib SM, LaPointe NM, Kramer JM, et al. What clinicians should know about the QT interval. JAMA. 2003;289(16): 2120-2127.
2. Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy. 2003;23(7):881-908.
3. Bednar MM, Harrigan EP, Ruskin JN. Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol. 2002;89(11):1316-1319.
4. Dekker JM, Crow RS, Hannan PJ, et al. Heart rate-corrected QT interval prolongation predicts risk of coronary heart disease in black and white middle-aged men and women: the ARIC study. J Am Coll Cardiol. 2004;43(4):565-571.
5. Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270(21):2590-2597.
6. Gowda RM, Khan IA, Wilbur SL, et al. Torsade de pointes: the clinical considerations. Int J Cardiol. 2004;96(1):1-6.
7. LaPointe NM, Al-Khatib SM, Kramer JM, et al. Knowledge deficits related to the QT interval could affect patient safety. Ann Noninvasive Electrocardiol. 2003;8(2):157-160.
8. US Department of Health and Human Services. Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. In: (CDER) CfDEaR, ed. Guidance for Industry. Rockville; 2002:1-15.
9. Meierhenrich R, Helguera ME, Kidwell GA, et al. Influence of amiodarone on QT dispersion in patients with life-threatening ventricular arrhythmias and clinical outcome. Int J Cardiol. 1997;60(3):289-294.
10. Bonnemeier H, Ortak J, Tolg R, et al. Carvedilol versus metoprolol in patients undergoing direct percutaneous coronary interventions for myocardial infarction: effects on QT dynamicity. Pacing Clin Electrophysiol. 2005;28(suppl 1):S217-S221.
11. Lee SP, Harris ND, Robinson RT, et al. Effect of atenolol on QTc interval lengthening during hypoglycaemia in type 1 diabetes. Diabetologia. 2005;48(7):1269-1272.
12. Piccirillo G, Quaglione R, Nocco M, et al. Effects of long-term beta-blocker (metoprolol or carvedilol) therapy on QT variability in subjects with chronic heart failure secondary to ischemic cardiomyopathy. Am J Cardiol. 2002;90(10):1113-1117.
13. Yildirir A, Sade E, Tokgozoglu L, et al. The effects of chronic carvedilol therapy on QT dispersion in patients with congestive heart failure. Eur J Heart Fail. 2001;3(6):717-721.
14. Yoshiga Y, Shimizu A, Yamagata T, et al. Beta-blocker decreases the increase in QT dispersion and transmural dispersion of repolarization induced by bepridil. Circ J. 2002;66(11):1024-1028.
15. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task force on sudden cardiac death, european society of cardiology. Europace. 2002;4(1):3-18.
16. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292(11):1341-1344.
17. Robbins J, Nelson JC, Rautaharju PM, et al. The association between the length of the QT interval and mortality in the Cardiovascular Health Study. Am J Med. 2003;115(9):689-694.
18. Haefeli WE, Schoenenberger RA, Weiss P, et al. Possible risk for cardiac arrhythmia related to intravenous erythromycin. Intensive Care Med. 1992;18(8):469-473.
19. Metzger E, Friedman R. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol. 1993;13(2):128-132.
20. Middlekauff HR, Stevenson WG, Saxon LA, et al. Amiodarone and torsades de pointes in patients with advanced heart failure. Am J Cardiol. 1995;76(7):499-502.
21. Osada M, Tanaka Y, Komai T, et al. QT dispersion in patients with severe burns in intensive care unit. Intensive Care Med. 2000;26(10):1581.
22. Perrault LP, Denault AY, Carrier M, et al. Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery. Can J Anaesth. 2000;47(3):251-254.
23. Artucio H, Pereira M. Cardiac arrhythmias in critically ill patients: epidemiologic study. Crit Care Med. 1990;18(12): 1383-1388.
24. Reinelt P, Karth GD, Geppert A, et al. Incidence and type of cardiac arrhythmias in critically ill patients: a single center experience in a medical-cardiological ICU. Intensive Care Med. 2001;27(9):1466-1473.
25. Bayer Pharmaceuticals. Product Information: Avelox(R) tablets, Avelox(R) IV injection, moxifloxacin hydrochloride tablets, moxifloxacin hydrochloride in sodium chloride injection. West Haven, CT: Bayer Pharmaceuticals; 2004.
26. Olsen K, Pathak R, Ng T. Comparison of ciprofloxacin and moxifloxacin, and associated risk factors on QTc prolongation in critically ill patients. Crit Care Med. 2003;31(suppl 1):231A.
27. Antzelevitch C. Arrhythmogenic mechanisms of QT prolonging drugs: is QT prolongation really the problem? J Electrocardiol. 2004;37(suppl):15-24.
28. Malik M, Batchvarov VN. Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol. 2000;36(6): 1749-1766.
29. Shah RR. Drug-induced QT dispersion: does it predict the risk of torsade de pointes? J Electrocardiol. 2005;38(1):10-18.